UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (381) 381
life sciences & biomedicine (376) 376
humans (371) 371
canagliflozin (340) 340
diabetes mellitus, type 2 - drug therapy (305) 305
diabetes (222) 222
type 2 diabetes (204) 204
male (198) 198
female (192) 192
hypoglycemic agents - therapeutic use (192) 192
middle aged (170) 170
hypoglycemic agents - adverse effects (167) 167
glucose (159) 159
canagliflozin - therapeutic use (155) 155
endocrinology & metabolism (155) 155
sodium-glucose transporter 2 - antagonists & inhibitors (148) 148
canagliflozin - adverse effects (131) 131
aged (127) 127
glucosides - therapeutic use (125) 125
type 2 diabetes mellitus (107) 107
diabetes mellitus (101) 101
pharmacology & pharmacy (98) 98
adult (97) 97
glucosides - adverse effects (96) 96
dapagliflozin (95) 95
treatment outcome (91) 91
diabetes mellitus, type 2 - blood (89) 89
hypoglycemic agents - administration & dosage (89) 89
general & internal medicine (85) 85
medicine, general & internal (85) 85
dextrose (84) 84
empagliflozin (84) 84
blood pressure (81) 81
sodium (76) 76
thiophenes - therapeutic use (76) 76
blood glucose - drug effects (75) 75
clinical trials (74) 74
drug therapy (74) 74
benzhydryl compounds - therapeutic use (70) 70
blood glucose - metabolism (70) 70
sglt2 inhibitor (68) 68
canagliflozin - administration & dosage (66) 66
care and treatment (63) 63
double-blind method (62) 62
thiophenes - adverse effects (62) 62
risk factors (58) 58
body weight (57) 57
internal medicine (56) 56
diabetes mellitus, type 2 - complications (54) 54
analysis (51) 51
glucosides - administration & dosage (51) 51
insulin (51) 51
hypoglycemic agents - pharmacology (50) 50
diabetes therapy (49) 49
sodium-glucose transporter 2 inhibitors - adverse effects (48) 48
glycated hemoglobin a - metabolism (47) 47
diabetes mellitus, type 2 - metabolism (45) 45
dose-response relationship, drug (45) 45
randomized controlled trials as topic (45) 45
benzhydryl compounds - adverse effects (44) 44
drug therapy, combination (44) 44
cardiovascular disease (43) 43
hemoglobin (43) 43
medicine & public health (43) 43
patients (43) 43
sodium-glucose transporter 2 inhibitors - therapeutic use (43) 43
abridged index medicus (42) 42
blood pressure - drug effects (42) 42
hypoglycemic agents (42) 42
sodium-glucose transporter 2 - metabolism (42) 42
endocrinology (41) 41
thiophenes - administration & dosage (41) 41
glucosides - pharmacology (40) 40
hypoglycemia (37) 37
medical research (36) 36
medicine, research & experimental (36) 36
research & experimental medicine (36) 36
review (36) 36
safety (36) 36
glucose transporter (35) 35
body mass index (34) 34
canagliflozin - pharmacology (34) 34
metformin (34) 34
research (34) 34
sodium-glucose transporter 2 inhibitors (34) 34
cardiovascular diseases (33) 33
diabetes mellitus, type 2 - physiopathology (33) 33
kidneys (33) 33
sodium glucose co-transporter 2 inhibitor (33) 33
animals (32) 32
glycosylated hemoglobin (32) 32
hyperglycemia (32) 32
studies (32) 32
body weight - drug effects (31) 31
heart failure (31) 31
hypoglycemia - chemically induced (31) 31
kidney diseases (31) 31
young adult (31) 31
complications and side effects (30) 30
kidney - drug effects (30) 30
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (488) 488
German (5) 5
Chinese (2) 2
Danish (1) 1
French (1) 1
Hungarian (1) 1
Japanese (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetologia, ISSN 0012-186X, 12/2013, Volume 56, Issue 12, pp. 2582 - 2592
Sodium glucose co-transporter 2 (SGLT2) inhibitor | Medicine & Public Health | Human Physiology | Canagliflozin | Metabolic Diseases | Internal Medicine | Sitagliptin | Metformin | Type 2 diabetes mellitus | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Diabetes. Impaired glucose tolerance | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Blood Pressure | Triazoles - administration & dosage | Triazoles - adverse effects | Thiophenes - adverse effects | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Pyrazines - administration & dosage | Glycated Hemoglobin A - drug effects | Body Weight - drug effects | Lipids | Male | Thiophenes - administration & dosage | Metformin - adverse effects | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Female | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Glucosides - adverse effects | Fasting | Treatment Outcome | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Glucosides - administration & dosage | Adolescent | Pyrazines - adverse effects | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Complications and side effects | Care and treatment | Body weight | Glucose | Comparative analysis | Dextrose | Index Medicus
Journal Article
Journal Article
International journal of clinical practice (Esher), ISSN 1368-5031, 12/2013, Volume 67, Issue 12, pp. 1267 - 1282
Journal Article
Diabetes (New York, N.Y.), ISSN 0012-1797, 06/2018, Volume 67, Issue 6, pp. 1182 - 1189
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Gluconeogenesis - drug effects | Humans | Middle Aged | Male | Diabetes Mellitus, Type 2 - metabolism | Insulin - blood | Glucagon - blood | Glucagon - antagonists & inhibitors | Glucagon - agonists | Hypoglycemia - prevention & control | Drug Therapy, Combination - adverse effects | Glucagon-Secreting Cells - drug effects | Insulin-Secreting Cells - metabolism | Canagliflozin - therapeutic use | Glucagon-Secreting Cells - metabolism | Adult | Female | Hypoglycemia - chemically induced | Insulin Secretion | Hypoglycemic Agents - therapeutic use | Hyperglycemia - prevention & control | Reproducibility of Results | Insulin - agonists | Sodium-Glucose Transporter 2 - metabolism | Sodium-Glucose Transporter 2 Inhibitors | Canagliflozin - adverse effects | Down-Regulation - drug effects | Diabetes Mellitus, Type 2 - blood | Insulin - metabolism | Insulin-Secreting Cells - drug effects | Insulin - chemistry | Liraglutide - adverse effects | Incretins - adverse effects | Liraglutide - therapeutic use | Membrane Transport Modulators - therapeutic use | Glucagon - metabolism | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Membrane Transport Modulators - adverse effects | Hypoglycemic Agents - adverse effects | Type 2 diabetes | Dosage and administration | Research | Drug therapy, Combination | Drug therapy | Liraglutide | Glucagon | Cardiomyopathy | Diabetes mellitus | Clinical trials | Diabetes | Glucose | Epidemiology | Diabetes mellitus (non-insulin dependent) | Insulin | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes care, ISSN 0149-5992, 03/2015, Volume 38, Issue 3, pp. 403 - 411
Journal Article
Journal Article